<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583813</url>
  </required_header>
  <id_info>
    <org_study_id>MGH_001</org_study_id>
    <nct_id>NCT04583813</nct_id>
  </id_info>
  <brief_title>Empagliflozin and Atrial Fibrillation Treatment</brief_title>
  <acronym>EMPA-AF</acronym>
  <official_title>Efficacy of Empagliflozin in Patients With Heart Failure and Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miulli General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Miulli General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared&#xD;
      with placebo, in patients with diabetes mellitus or overweight, heart failure and atrial&#xD;
      fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 24-month randomized, single-blind, placebo-controlled trial to investigate the efficacy of&#xD;
      empagliflozin to reduce atrial fibrillation burden in patients with diabetes mellitus or&#xD;
      overweight, heart failure and atrial fibrillation in which a rhythm control strategy is&#xD;
      indicated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maintenance of sinus rhythm after the blanking period</measure>
    <time_frame>From 90 days after baseline to 24-months</time_frame>
    <description>To compare the proportion of patients with sinus rhythm from 90 days after baseline to end of study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of major adverse cardiovascular events</measure>
    <time_frame>Baseline through 24-months</time_frame>
    <description>To compare the incidence at the end of study period of major adverse cardiovascular events (death, non-fatal myocardial infarction, acute cerebrovascular events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations for cardiovascular events</measure>
    <time_frame>Baseline through 24-months</time_frame>
    <description>To compare the incidence at the end of study period of hospitalizations for cardiovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint: Incidence of adverse events</measure>
    <time_frame>Baseline through 24-months</time_frame>
    <description>To estimate the incidence of adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Economic burden of hospitalizations for cardiovascular events</measure>
    <time_frame>Baseline through 24-months</time_frame>
    <description>To compare economic burden of hospitalizations for cardiovascular events estimated as the hospital reimbursement from National Health Service for cardiovascular admissions during study period</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in measure of the adverse effects of heart failure on patient's life</measure>
    <time_frame>Baseline, 1, 3, 6, 12 and 24 month</time_frame>
    <description>To compare changes in adverse effects of heart failure on patient's life evaluated by using the Minnesota Living with Heart Failure Questionnaire. The total score range is 0 to 105, with higher scores indicating more significant impairment in health-related quality of life. A total score decrease indicates the amelioration of the quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in patient's perception of health status</measure>
    <time_frame>Baseline, 1, 3, 6, 12 and 24 month</time_frame>
    <description>To compare changes in perception of health status evaluated by using the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12). The total score range is 0 to 100, with higher scores indicating a better condition. A total score increase indicates amelioration of quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in patient's functional capacity</measure>
    <time_frame>Baseline, 1, 3, 6, 12 and 24 month</time_frame>
    <description>To compare changes in functional capacity evaluated by using the Six Minutes Walk Test. The distance covered over a time of 6 minutes measures functional capacity. An increase in the distance walked indicates improvement in the patient's condition.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Failure</condition>
  <condition>Obesity</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Empagliflozin 10 mg oral tablet, once daily, for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Empagliflozin matching placebo oral tablet, once daily for 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Empagliflozin 10 mg oral tablet, once daily, for 24 months</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Empagliflozin 10 mg oral tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Empagliflozin matching placebo, once daily, for 24 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo oral tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-80 years&#xD;
&#xD;
          2. Diabetes mellitus or Body Mass Index over 25 Kg/m2&#xD;
&#xD;
          3. Heart failure&#xD;
&#xD;
          4. New York Heart Association (NYHA) Functional Classification: II or III&#xD;
&#xD;
          5. Documented atrial fibrillation&#xD;
&#xD;
          6. Understands the nature of the study, treatment procedure and provides written informed&#xD;
             consent&#xD;
&#xD;
          7. Willing to comply with specified pre-, post- and follow-up testing, evaluations and&#xD;
             requirements&#xD;
&#xD;
          8. Expected to remain available for at least 24 months after enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Permanent atrial fibrillation&#xD;
&#xD;
          2. Current use or prior use of a sodium-glucose co-transporter (SGLT) 2 inhibitor or&#xD;
             combined inhibitor of SGLT-1 and SGLT-2 (all the other antidiabetic drugs are&#xD;
             permitted performing an accurate glycemic control)&#xD;
&#xD;
          3. Known allergy or hypersensitivity to any SGLT-2 inhibitors&#xD;
&#xD;
          4. History of ketoacidosis&#xD;
&#xD;
          5. Need or wish to continue the intake of restricted medications or any drug considered&#xD;
             likely to interfere with the safe conduct of the trial&#xD;
&#xD;
          6. New York Heart Association (NYHA) Functional Classification: I or IV&#xD;
&#xD;
          7. Unstable angina&#xD;
&#xD;
          8. Presence of any disease that is likely to shorten life expectancy to &lt; 1 year&#xD;
&#xD;
          9. Any cardiac surgery within three months prior to enrolment&#xD;
&#xD;
         10. Awaiting cardiac transplantation or other cardiac surgery within the next year&#xD;
&#xD;
         11. Myocardial infarction within 60 days prior to enrolment&#xD;
&#xD;
         12. Contraindications to oral anticoagulation&#xD;
&#xD;
         13. Active systemic infection or sepsis&#xD;
&#xD;
         14. Left atrial thrombus (e.g., transesophageal echocardiography, computed tomography and&#xD;
             intracardiac echocardiography)&#xD;
&#xD;
         15. History of a documented thromboembolic event such as stroke or transient ischemic&#xD;
             neurological attack in the three months prior to enrollment&#xD;
&#xD;
         16. Currently enrolled in another trial that has not completed the required follow-up&#xD;
             period and would conflict with this study&#xD;
&#xD;
         17. Chronic liver diseases&#xD;
&#xD;
         18. Chronic kidney disease (creatinine clearance &lt; 45 ml/min)&#xD;
&#xD;
         19. Pregnant or breast-feeding mothers&#xD;
&#xD;
         20. Any other clinical condition that might jeopardize patient safety during participation&#xD;
             in this trial or prevent the subject from adhering to the trial protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Di Monaco, MD</last_name>
    <phone>+390803054357</phone>
    <email>a.dimonaco@miulli.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Miulli General Hospital</name>
      <address>
        <city>Acquaviva Delle Fonti</city>
        <state>Bari</state>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonio Di Monaco, MD</last_name>
      <phone>+390803054357</phone>
      <email>a.dimonaco@miulli.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Grimaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Di Monaco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Miulli General Hospital</investigator_affiliation>
    <investigator_full_name>Massimo Grimaldi</investigator_full_name>
    <investigator_title>Head of Arrhythmology and Electrophysiology Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

